NRx Pharmaceuticals, Inc. announced that Matthew Rockefeller has joined the advisory board of HOPE Therapeutics, its wholly-owned subsidiary. This appointment was revealed during keynote talks presented by NRx CEO, Prof. Jonathan Javitt, at the 2025 Global Passion Project, sponsored by the Rockefeller Global Family Office.
The presentations detailed plans for the Fall 2025 launch of HOPE Therapeutics clinics and a unique one-week residential program. This program targets suicidal depression, PTSD, traumatic brain injury, and cognitive dysfunction, aiming to combine neuroplastic drugs like ketamine and cycloserine with transcranial magnetic stimulation and hyperbaric oxygen therapy.
The residential program will be the nation’s first to integrate nutritional therapy, neuroplastic-targeted outdoor activities, and supportive therapy in a campus-like setting. HOPE Therapeutics aims for a response rate of over 90% with these combined treatment modalities, which will be available at multiple locations in Florida and elsewhere this Fall.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.